Personal prescription importation to be blocked
The Canadian International Pharmacy Association (CIPA) has been informed directly by Zonos that new U.S. Customs entry requirements will make importation of personal use prescription medications a thing of the past.
Zonos is the customs broker of record for nearly every major international mail system in the world. For most of those systems, it is currently the only customs broker they are working with in that capacity. Its ability to process prescription shipments therefore directly affects whether those parcels can enter the United States.
As communicated to CIPA, the requirements described below were dictated to Zonos by U.S. Customs and Border Protection (CBP) and will be enforced beginning October 22. They are not an independent operational or commercial decision by Zonos.
Zonos confirmed that, beginning October 22, it will not act as importer of record for pharmaceutical shipments where either:
1. The pharmaceutical product is othewise commercially availble in the United States, or
2.The product was purchased through a supply chain in which any person or entity markets to American consumers.
These circumstances encompass virtually all routine prescription orders placed by American patients with licensed Canadian and international pharmacy services.
There is also public supporting information. Zonos's published guidance states: "If effective treatment is already available in the US, the exemption does not apply." It also explains that additional patient paperwork does not overcome the issue of a pharmacy marketing to U.S. residents. The broader supply-chain position described above was confirmed directly in CIPA's meeting with Zonos.
The post correctly identifies an October 22, 2026 compliance date in the official CBP rule. But recognizing that the rule changes customs-entry procedures does not establish that ordinary prescription parcels will continue to clear under those procedures.
The alternative Entry Type 13 process requires a qualified importer of record, a customs bond, electronic filings, and the applicable regulatory information. It does not waive the underlying requirements governing whether a medication may enter. Those obligations are documented in CBP's Entry Type 13 notice.
Changing an entry type therefore does not resolve the problem. Nor does pointing to the continued existence of discretionary personal-importation criteria establish that routine pharmacy orders will satisfy those criteria or that a broker can process them under the requirements communicated by CBP.
The distinction between a newly worded blanket prohibition and the practical closure of a shipping pathway matters when describing the law. But patients still need to know whether their medication will reach them. Our warning addresses that practical outcome, based on both the published requirements and direct confirmation of their planned implementation.
Based on that information, we expect the planned implementation to prevent virtually all routine personal-use prescription shipments from licensed Canadian and international pharmacies from reaching American patients beginning October 22, unless the policy or its implementation changes.
Members of CIPA have a duty to inform people while they still have time to make arrangements. Waiting until shipments can no longer reach patients would fail those who depend on them.
